829 related articles for article (PubMed ID: 31203996)
1. Venetoclax-based therapies for acute myeloid leukemia.
Guerra VA; DiNardo C; Konopleva M
Best Pract Res Clin Haematol; 2019 Jun; 32(2):145-153. PubMed ID: 31203996
[TBL] [Abstract][Full Text] [Related]
2. New drugs creating new challenges in acute myeloid leukemia.
Tiong IS; Wei AH
Genes Chromosomes Cancer; 2019 Dec; 58(12):903-914. PubMed ID: 30861214
[TBL] [Abstract][Full Text] [Related]
3. Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML.
Wei AH; Tiong IS
Blood; 2017 Dec; 130(23):2469-2474. PubMed ID: 29051180
[TBL] [Abstract][Full Text] [Related]
4. What to use to treat AML: the role of emerging therapies.
Thol F
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):16-23. PubMed ID: 34889359
[TBL] [Abstract][Full Text] [Related]
5. New drugs approved for acute myeloid leukaemia in 2018.
Kucukyurt S; Eskazan AE
Br J Clin Pharmacol; 2019 Dec; 85(12):2689-2693. PubMed ID: 31469910
[TBL] [Abstract][Full Text] [Related]
6. How I treat acute myeloid leukemia in the era of new drugs.
DiNardo CD; Wei AH
Blood; 2020 Jan; 135(2):85-96. PubMed ID: 31765470
[TBL] [Abstract][Full Text] [Related]
7. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Kantarjian HM; Kadia TM; DiNardo CD; Welch MA; Ravandi F
Cancer; 2021 Apr; 127(8):1186-1207. PubMed ID: 33734442
[TBL] [Abstract][Full Text] [Related]
8. Single-agent and combination biologics in acute myeloid leukemia.
Richard-Carpentier G; DiNardo CD
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):548-556. PubMed ID: 31808888
[TBL] [Abstract][Full Text] [Related]
9. Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options.
Richardson DR; Green SD; Foster MC; Zeidner JF
Curr Hematol Malig Rep; 2021 Feb; 16(1):97-111. PubMed ID: 33609248
[TBL] [Abstract][Full Text] [Related]
10. [New therapeutic agents for acute myeloid leukemia].
Hosono N
Rinsho Ketsueki; 2019; 60(9):1108-1119. PubMed ID: 31597834
[TBL] [Abstract][Full Text] [Related]
11. Shutting Down Acute Myeloid Leukemia and Myelodysplastic Syndrome with BCL-2 Family Protein Inhibition.
Sharma P; Pollyea DA
Curr Hematol Malig Rep; 2018 Aug; 13(4):256-264. PubMed ID: 29982865
[TBL] [Abstract][Full Text] [Related]
12. New directions for emerging therapies in acute myeloid leukemia: the next chapter.
Daver N; Wei AH; Pollyea DA; Fathi AT; Vyas P; DiNardo CD
Blood Cancer J; 2020 Oct; 10(10):107. PubMed ID: 33127875
[TBL] [Abstract][Full Text] [Related]
13. Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?
Estey E; Karp JE; Emadi A; Othus M; Gale RP
Leukemia; 2020 Mar; 34(3):671-681. PubMed ID: 31915366
[TBL] [Abstract][Full Text] [Related]
14. Recently approved therapies in acute myeloid leukemia: A complex treatment landscape.
Talati C; Sweet K
Leuk Res; 2018 Oct; 73():58-66. PubMed ID: 30223250
[TBL] [Abstract][Full Text] [Related]
15. AML: New Drugs but New Challenges.
Burnett A; Stone R
Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):341-350. PubMed ID: 32151586
[TBL] [Abstract][Full Text] [Related]
16. Is the overall survival for older adults with AML finally improving?
Lancet JE
Best Pract Res Clin Haematol; 2018 Dec; 31(4):387-390. PubMed ID: 30466753
[TBL] [Abstract][Full Text] [Related]
17. Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia.
Griffiths EA; Carraway HE; Chandhok NS; Prebet T
Leuk Res; 2020 Apr; 91():106339. PubMed ID: 32146154
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
[TBL] [Abstract][Full Text] [Related]
19. 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models.
Garg R; Allen KJH; Dawicki W; Geoghegan EM; Ludwig DL; Dadachova E
Cancer Med; 2021 Feb; 10(3):1128-1140. PubMed ID: 33347715
[TBL] [Abstract][Full Text] [Related]
20. Comparison of venetoclax and ivosidenib/enasidenib for unfit newly diagnosed patients with acute myeloid leukemia and
Wang L; Song J; Xiao X; Li D; Liu T; He X
J Chemother; 2024 May; 36(3):202-207. PubMed ID: 37599456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
